Abstract
Low-volatility organophosphorus chemical warfare agents (OP CWAs) are cholinesterase inhibitors which easily absorb into the skin, leading to the formation of a dermal depot from which they slowly enter the bloodstream. This leads to sustained cholinergic hyperstimulation, which if untreated may lead to death. However, current available countermeasures are not adequate to neutralize the agent residing in the dermal depot. Accordingly, we evaluated the efficacy of the potassium salt of acetohydroxamic acid (880 mg/ml in DMSO/H2O 1:4, AHAK), as a potential “catch-up” therapy lotion intended to neutralize the dermal depot, by penetrating the skin and decomposing it before it reaches the bloodstream. To that end, we compared the clinical outcome following skin surface decontamination combined with antidotal treatment, to that following the same antidotal treatment combined with dermal application of AHAK at the site of VX exposure, against percutaneous poisoning by a lethal neat dose (4 mg/kg) of the low-volatility nerve agent VX, in an unanesthetized swine model. Following skin surface decontamination and antidotal treatment, recurrence of intoxication signs and a prolonged recovery time were observed. In contrast, similar antidotal treatment combined with dermal application of AHAK significantly reduced intoxication signs recurrences and accordingly medical supervision duration needed, paralleled by a significantly faster recovery of whole blood cholinesterase activity. An initial evaluation demonstrated the safety of prolonged whole-body AHAK application. Hence, the AHAK lotion may act as an efficient “catch-up” therapy against percutaneous poisoning by low-volatility OP CWAs, improving the clinical outcome and reducing the burden on medical staff.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All the data in this article will be made available on request to the corresponding author.
Abbreviations
- AChE:
-
Acetylcholinesterase
- AHA:
-
Acetohydroxamic acid
- AHAK:
-
The potassium salt of AHA in DMSO/H2O 1:4
- ChE:
-
Cholinesterase
- CWA:
-
Chemical warfare agent
- FE:
-
Fuller’s Earth
- OP:
-
Organophosphorus
- RSDL:
-
Reactive skin decontamination lotion
- TAB:
-
TMB-4, Atropine and benactyzine
References
Acetohydroxamic acid PubChem (2023). https://pubchem.ncbi.nlm.nih.gov/compound/1990. Accessed 22 May 2023
Aurbek N, Thiermann H, Szinicz L, Eyer P, Worek F (2006) Analysis of inhibition, reactivation and aging kinetics of highly toxic organophosphorus compounds with human and pig acetylcholinesterase. Toxicology 224:91–99. https://doi.org/10.1016/j.tox.2006.04.030
Bloch-Shilderman E, Rabinovitz I, Egoz I, Yacov G, Allon N, Nili U (2018) Determining a threshold sub-acute dose leading to minimal physiological alterations following prolonged exposure to the nerve agent VX in rats. Arch Toxicol 92:873–892. https://doi.org/10.1007/s00204-017-2108-5
Bloch-Shilderman E, Yacov G, Cohen L, Egoz I, Gutman H, Gez R, Rabinovitz I, Nili U (2019) Repetitive antidotal treatment is crucial in eliminating eye pathology, respiratory toxicity and death following whole-body VX vapor exposure in freely moving rats. Arch Toxicol 93:1365–1384. https://doi.org/10.1007/s00204-019-02401-0
Braue EH Jr, Smith KH, Doxzon BF, Lumpkin HL, Clarkson ED (2011) Efficacy studies of reactive skin decontamination lotion, M291 skin decontamination kit, 0.5% bleach, 1% soapy water, and skin exposure reduction paste against chemical warfare agents, part 1: guinea pigs challenged with VX. Cutan Ocul Toxicol 30:15–28. https://doi.org/10.3109/15569527.2010.515281
Chilcott RP, Dalton CH, Hill I, Davidson CM, Blohm KL, Hamilton MG (2003) Clinical manifestations of VX poisoning following percutaneous exposure in the domestic white pig. Hum Exp Toxicol 22:255–261. https://doi.org/10.1191/0960327103ht359oa
Chilcott RP, Dalton CH, Hill I, Davison CM, Blohm KL, Clarkson ED, Hamilton MG (2005a) In vivo skin absorption and distribution of the nerve agent VX (O-ethyl-S-[2(diisopropylamino)ethyl] methylphosphonothioate) in the domestic white pig. Hum Exp Toxicol 24:347–352. https://doi.org/10.1191/0960327105ht537oa
Chilcott RP, Dalton CH, Hill I, Davison CM, Blohm KL, Clarkson ED, Hamilton MG (2005b) Evaluation of a barrier cream against the chemical warfare agent VX using the domestic white pig. Basic Clin Pharmacol Toxicol 97:35–38. https://doi.org/10.1111/j.1742-7843.2005.pto_97106.x
Craig FN, Cummings EG, Sim VM (1977) Environmental temperature and the percutaneous absorption of a cholinesterase inhibitor, VX. J Investig Dermatol 68:357–361. https://doi.org/10.1111/1523-1747
Dalton CH, Hattersley IJ, Rutter SJ, Chilcott RP (2006) Absorption of the nerve agent VX (O-ethyl-S-[2(di-isopropylamino)ethyl] methyl phosphonothioate) through pig, human and guinea pig skin in vitro. Toxicol in Vitro 20:1532–1536. https://doi.org/10.1016/J.TIV.2006.06.009
Dorandeu F, Mikler JR, Thiermann H, Tenn C, Davidson C, Sawyer TW, Lallement G, Worek F (2007) Swine models in the design of more effective medical countermeasures against organophosphorus poisoning. Toxicology 233:128–144. https://doi.org/10.1016/j.tox.2006.09.013
Feldman S, Putcha L, Griffith DP (1978) Pharmacokinetics of acetohydroxamic acid. Preliminary Investigation. Investig Urol 15:498–501
Fémy F, Meesemaecker G, Belverge N, Courageux C, Nervo A, Goulay R, Reymond C, Chantegreil F, Madi M, Nachon F, Taudon N, Jafré N (2023) Toxicokinetics of plasmatic VX in a swine model: comparison of a simple enzymatic titration method with a mass spectrometry method. Arch Toxicol 97:421–428. https://doi.org/10.1007/s00204-022-03408-w
Frosch PJ, Kligman AM (1979) The soap chamber test. A new method for assessing the irritancy of soaps. J Am Acad Dermatol 1:35–41. https://doi.org/10.1016/s0190-9622(79)70001-6
Grob D, Harvey JC (1958) Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate). J Clin Investig 37:350–368. https://doi.org/10.1172/JCI103615
Hamilton MG, Hill I, Conley J, Sawyer TW, Caneva DC, Lundy PM (2004) Clinical aspects of percutaneous poisoning by the chemical warfare agent VX: effects of application site and decontamination. Mil Med 169:856–862. https://doi.org/10.7205/milmed.169.11.856
Hartmann HM (2002) Evaluation of risk assessment guideline levels for the chemical warfare agents mustard, GB, and VX. Reg Toxicol Pharmacol 35:347–356. https://doi.org/10.1006/rtph.2002.1547
Hrvat NM, Kovarik Z (2020) Counteracting poisoning with chemical warfare nerve agents. Arh Hig Rada Toksikol 71:266–284. https://doi.org/10.2478/aiht-2020-71-3459
Johnson CD, Russell RL (1975) A rapid simple radiometric assay for cholinesterase suitable for multiple determinations. Anal Biochem 64:229–238. https://doi.org/10.1016/0003-2697(75)90423-6
Joosen MJA, van der Schans MJ, van Helden HPM (2010) Percutaneous exposure to the nerve agent VX: efficacy of combined atropine, obidoxime and diazepam treatment. Chem Biol Interact 188:255–263. https://doi.org/10.1016/j.cbi.2010.06.010
Joosen MJA, van der Schans MJ, Kuijpers WC, van Helden HPM, Noort D (2013) Timing of decontamination and treatment in case of percutaneous VX poisoning: a mini review Chem. Biol Interact 203:149–153. https://doi.org/10.1016/j.cbi.2012.10.002
Joosen MJ, van den Berg RM, de Jong AL, van der Schans MJ, Noort D, Langenberg JP (2017) The impact of skin decontamination on the time window for effective treatment of percutaneous VX exposure. Chem Biol Interact 267:48–56. https://doi.org/10.1016/j.cbi.2016.02.001
KYODO NEWS (2017) https://english.kyodonews.net/news/2017/10/77b81fbc673e-accused-killers-of-kim-jong-nam-seemingly-unaffected-by-vx-exposure.html
Lithostat official label (2023) https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6660b616-a82d-9109-19ce-2bdf9747acea&type=display Accessed 22 May 2023
Marrs TC (2007) Toxicology of organophosphate nerve agents. In: Marrs TC, Maynard RL, Sidell F (eds) Chemical warfare agents: toxicology and treatment, 2nd edn. Wiley, Chichester, pp 191–222. https://doi.org/10.1002/9780470060032.ch8
Mason HJ (2000) The recovery of plasma cholinesterase and erythrocyte acetylcholinesterase activity in workers after over-exposure to dichlorvos. Occup Med 50:343–347. https://doi.org/10.1093/occmed/50.5.343
Munro NB, Ambrose KR, Watson AP (1994) Toxicity of the organophosphate chemical warfare agents GA, GB, and VX: implications for public protection. Environ Health Perspect 102:18–38. https://doi.org/10.1289/ehp.9410218
Nahum V, Nili U, Bloch-Shilderman E, Smolkin B, Ashkenazi N (2021) Towards catch-up therapy: evaluation of nucleophilic active pharmaceutical ingredients for the treatment of percutaneous VX poisoning, in-vial and in-vitro studies. Int J Pharm 603:120689. https://doi.org/10.1016/j.ijpharm.2021.120689
Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7:27–31. https://doi.org/10.4103/0976-0105.177703
Nozaki H, Aikawa N, Fujishima S, Suzuki M, Shinozawa Y, Hori S, Nogawa S (1995) A case of VX poisoning and the difference from sarin. Lancet 346:698–699. https://doi.org/10.1016/S0140-6736(95)92306-3
Putcha L, Griffith DP, Feldman S (1985) Pharmacokinetics of acetohydroxamic acid in patients with staghorn renal calculi. Eur J Clin Pharmacol 28:439–445. https://doi.org/10.1007/BF00544364
Rice H, Dalton CH, Price ME, Graham SJ, Green AC, Jenner J, Groombridge HJ, Timperley CM (2015) Toxicity and medical countermeasure studies on the organophosphorus nerve agents VM and VX. Proc Math Phys Eng Sci 471(2176):20140891. https://doi.org/10.1098/rspa.2014.0891
Rolland P, Bolzinger MA, Cruz C, Josse D, Briançon S (2013) Hairy skin exposure to VX in vitro: effectiveness of delayed decontamination. Toxicol in Vitro 27:358–366. https://doi.org/10.1016/j.tiv.2012.08.014
Rosenberg Y, Saxena A (2020) Acetylcholinesterase inhibition resulting from exposure to inhaled OP can be prevented by pretreatment with BChE in both macaques and minipigs. Neuropharmacology 174:108150. https://doi.org/10.1016/j.neuropharm.2020.108150
RSDL website (2023) https://www.rsdl.com/. Accessed 17 May 2023
Schwartz MD, Hurst CG, Kirk MA, Reedy SJD, Braue EH Jr (2012) Reactive skin decontamination lotion (RSDL) for the decontamination of chemical warfare agent (CWA) dermal exposure. Curr Pharm Biotechnol 13:1971–1979. https://doi.org/10.2174/138920112802273191
Sidell FR, Groff WA (1971) Intramuscular and intravenous administration of small doses of 2-pyridinium aldoxime methochloride to man. J Pharm Sci 60:1224–1228. https://doi.org/10.1002/jps.2600600823
Sim VM (1962) Variability of different intact human-skin sites to the penetration of VX. Technical report CRDLR 3122. U.S. Army Chemical Corps Research and Development Command, Chemical Research and Development Laboratories, Army Medical Center, MD. https://apps.dtic.mil/sti/pdfs/AD0271163.pdf. Accessed on 17 May 2023
Simon GA, Maibach HI (2000) The pig as an experimental animal model of percutaneous permeation in man: qualitative observations—an overview. Skin Pharmacol Appl Skin Physiol 13:229–234. https://doi.org/10.1159/000029928
Thiermann H, Aurbek N, Worek F (2016) Treatment of nerve agent poisoning. In: Worek F, Jenner J, Thiermann H (eds) Chemical warfare toxicology, volume 2 Management of poisoning. Royal Society of Toxicology, Cambridge, pp 1–42. https://doi.org/10.1039/9781782628071
Thors L, Lindberg S, Johansson S, Koch B, Koch M, Hägglund L, Bucht A (2017a) RSDL decontamination of human skin contaminated with the nerve agent VX. Toxicol Lett 269:47–54. https://doi.org/10.1016/j.toxlet.2017.02.001
Thors L, Koch M, Wigenstam E, Koch B, Hägglund L, Bucht A (2017b) Comparison of skin decontamination efficacy of commercial decontamination products following exposure to VX on human skin. Chem Biol Interact 273:82–89. https://doi.org/10.1016/j.cbi.2017.06.002
Thors L, Wigenstam E, Qvarnström J, Bucht A (2021) Efficient agent degradation within skin is important for decontamination of percutaneously exposed VX. Cutan Ocul Toxicol 40:95–102. https://doi.org/10.1080/15569527.2021.1902342
van der Schans MJ, Lander BJ, van der Wiel H, Langenberg JP, Benschop HP (2003) Toxicokinetics of the nerve agent (+/−)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration. Toxicol Appl Pharmacol 191:48–62. https://doi.org/10.1016/s0041-008x(03)00216-3
van der Schans MJ, Benschop HP, Whalley CE (2008) Toxicokinetics of nerve agents. In: Romano JA Jr, Lukey BJ, Salem H (eds) Chemical warfare agents: chemistry, pharmacology, toxicology, and therapeutics, 2nd edn. CRC Press Inc. pp 109–111. https://books.google.co.il/books?id=MGcnAIu4vyIC&printsec=frontcover&hl=iw#v=onepage&q&f=false
Wetherell JR, Armstrong SJ, Read RW, Clough GF (2008) VX penetration following percutaneous poisoning: a dermal microdialysis study in the guinea pig. Toxicol Mech Methods 18:313–321. https://doi.org/10.1080/15376510701884944
Willems JL, Langenberg JP, Verstraete AG, De Loose M, Vanhaesebroeck B, Goethals G, Belpaire FM, Buylaert WA, Vogelaers D, Colardyn F (1992) Plasma concentrations of pralidoxime methylsulphate in organophosphorus poisoned patients. Arch Toxicol 66:260–266. https://doi.org/10.1007/bf02307171
Worek F, Aurbek N, Willea T, Eyer P, Thiermann H (2011) Kinetic analysis of interactions of paraoxon and oximes with human, Rhesus monkey, swine, rabbit, rat and guinea pig acetylcholinesterase. Toxicol Lett 200:19–23. https://doi.org/10.1016/j.toxlet.2010.10.009
Yang YC (1999) Chemical detoxification of nerve agent VX. Acc Chem Res 32:109–115. https://doi.org/10.1021/ar970154s
Funding
Funding was provided by the Israeli Ministry of Defense.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest. The views expressed in this article are those of the authors and do not reflect the official policy of the IIBR (Israel Institute for Biological Research).
Ethics approval
The experimental procedures were approved by the Institutional Animal Care and Use Committee at the IIBR (Protocols No. P-07-20 and P-03-22) and are in strict accordance with the Guide for the Care and Use of Laboratory Animals, The National Academies Press, Washington DC, 2011. The study was designed to prevent any unnecessary animal discomfort.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Uri Nili, Eugenia Bloch-Shilderman: Equal contribution.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Bloch-Shilderman, E., Nili, U., Nahum, V. et al. “Catch-up" therapy: combining antidotal treatment with dermal application of AHA following percutaneous VX poisoning in the domestic swine. Arch Toxicol 97, 2771–2783 (2023). https://doi.org/10.1007/s00204-023-03574-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-023-03574-5